Axonis
Boston, US · 5 known investors
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain. The company translates discoveries from Boston Children's Hospital, Harvard, and Laval University into first-in-class and best-in-class treatments.
BiotechMedical Devices
Investors · 5
In the news
- Business Post (@businessposthq) on Xx.com · 2024
- Axonis Therapeutics bags $115m for neuromedicine developmentsiliconrepublic.com · 2024
- Axonis Therapeutics gets $115 million to treat paincen.acs.org · 2024
- With $115 million, biotech startup Axonis Therapeutics pivots to burgeoning pain fieldstatnews.com · 2024
- Axonis Therapeutics Raises $115M in Series A Financing to Advance Novel Neuromedicines | Venture Capitalventurecapital.com · 2024
- Axonis Therapeutics Raises $115M in Series A Financingfinsmes.com · 2024